Biocytogen Pharmaceuticals reached an agreement with BeiGene for licensing Biocytogen's fully human antibody RenMab/RenLite mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

RenMab and RenLite mice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology. In RenMab mice, the complete murine variable regions of the heavy and kappa light chains were replaced by full human heavy and kappa light chain V(D)J loci in situ; In RenLite mice, the variable regions of the murine heavy chain were completely replaced as in RenMab mice, and the whole murine variable regions of the κ light chain were replaced with a single human κ light chain VJ locus in situ. RenMab/RenLite mice can generate fully human antibody candidates with high affinity, specificity, and diversity for downstream antibody drug screening.

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs).

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. BeiGene currently has three approved medicines discovered and developed internally: BTK inhibitor BRUKINSA in the United States, China, the EU and Great Britain, Canada, Australia and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab as well as the PARP inhibitor pamiparib in China.